# Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

> **NCT02391116** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 67 (actual)

## Conditions studied

- Diffuse, Large B-Cell, Lymphoma

## Interventions

- **DRUG:** Copanlisib (Aliqopa, BAY80-6946)

## Key facts

- **NCT ID:** NCT02391116
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-08
- **Primary completion:** 2016-07-05
- **Final completion:** 2018-01-19
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2019-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02391116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02391116, "Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02391116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*